4577 — Daito Pharmaceutical Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeSmall CapSuper Stock

Annual income statement for Daito Pharmaceutical, fiscal year end - May 31st, JPY millions except per share, conversion factor applied.

	2022 May 31st	2023 May 31st	2024 May 31st	2025 May 31st	2026 May 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	JAS	JAS	JAS	JAS	JAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	43,464	45,101	46,895	50,643	50,650
Cost of Revenue
Gross Profit	11,459	10,331	9,839	8,638	9,897
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	37,166	39,920	43,032	48,180	47,091
Operating Profit	6,298	5,181	3,863	2,463	3,559
Total Net Non Operating Interest Income / Expense
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	6,720	5,076	4,218	2,958	4,065
Provision for Income Taxes
Net Income After Taxes	4,628	3,527	3,178	1,766	3,137
Minority Interest
Net Income Before Extraordinary Items
Net Income	4,668	3,599	3,294	1,909	3,162
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	4,668	3,600	3,295	1,908	3,161
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	158	114	106	65.8	110
Dividends per Share
Special Dividends per Share